Press Release
Q1FY24 Results, Press Release and Investor Presentation
Alkem Laboratories forays into Ophthalmology
Alkem Laboratories launches Cetuxa. World’s first biosimilar of Cetuximab for Head and Neck Cancer.
Q4FY23 Results, Press Release and Investor Presentation
Closure of US FDA Inspection at Ankleshwar
Closure of US FDA Inspection at Indore
Q3FY23 Results, Press Release and Investor Presentation
Q2FY23 Results, Press Release and Investor Presentation
Update on US FDA Inspection at St. Louis, USA
Update on US FDA Inspection at St. Louis, USA
Q1FY23 Results, Press Release and Investor Presentation
Q1FY23 Conference Call Invite.
Update on USFDA Inspection at Alkem’s manufacturing facility located at Indore.
Update on US FDA Inspection at St. Louis, USA
Update on MHRA Inspection at Alkem’s Bioequivalence Center at Taloja
Q4FY22 Results, Press Release and Investor Presentation
Q4FY22 Conference Call Invite.
Update on US FDA Inspection at Alkem’s Bioequivalence Center at Taloja
Update on ISP Chile Inspection at Alkem’s manufacturing facility located at Baddi, India.
Update on ISP Chile Inspection at Alkem's manufacturing facility located at Daman, India
Alkem signs a license agreement with Harvard University
Q3FY22 Results, Press Release and Investor Presentation
ALKEM enters into an exclusive license agreement with Johns Hopkins University
Q3FY22 and 9MFY22 Conference Call Invite
Q1FY22 Results, Press Release and Investor Presentation
Launch of Ibuprofen and Famotidine Tablets in the United States.
Update on US FDA Inspection at Bioequivalence center at Taloja.
Revised Conference Call Invite.
Q1FY22 Conference Call Invite.
Update on US FDA Inspection at St. Louis, USA.
Launch of Perampanel Tablets in India under the brand name 'Perampil'.
Q4FY21 Results, Press Release and Investor Presentation
Updates on partnership interest in ABCD Technologies LLP- 06.04.2021
Regulation 30 – Updates on partnership interest in ABCD Technologies LLP- 01.04.2021
Regulation 30 – Updates on partnership interest in ABCD Technologies LLP
Regulation 30 - Subscription of partnership interest in ABCD Technologies LLP
ALKEM partners with Tata Memorial Hospital
Launch of Brivaracetam in India under the brand name 'Brivasure'
Q3FY21 Results, Press Release and Investor Presentation
Q3FY21 Conference Call Invite
Q2FY21 Results, Press Release and Investor Presentation
Q2FY21 Conference Call Invite
Q1FY21 Results, Press Release and Investor Presentation
Launch of Favipiravir in India under the brand name "Alfluenza"
Q1FY21 Conference Call Invite
Q4FY20 Results, Press Release and Investor Presentation
Q4FY20 Conference Call Invite.
Closure of USFDA Inspection at St. Louis, USA.
Contribution towards PM CARES FUND
Closure of USFDA Inspection at Baddi, India
Update on USFDA Inspection at Baddi, India.
Q3FY20 Results, Press Release and Investor Presentation
Update on US FDA Inspection at St. Louis, USA.
Q3FY20 Conference Call Invite
Q2FY20 Results, Press Release and Investor Presentation
Closure of US FDA Inspection at Alkem’s manufacturing facility located at Daman, India and Baddi, India.
Q2FY20 Conference Call Invite
Update on USFDA Inspection at Bioequivalence Center at Taloja
Closure of USFDA Inspection at St. Louis, Fenton Logistics Park, USA September 12, 2019
Update on USFDA Inspection at Daman, India September 03, 2019
Update on USFDA Inspection at St. Louis, USA and Baddi, India August 24, 2019 August 24, 2019
Q1FY20 Results, Press Release and Investor Presentation August 12, 2019
Q1FY20 Conference Call Invite August 02, 2019
Closure of US FDA Inspection at Alkem's manufacturing facility located at Baddi, India July 30, 2019
Demise of Shri Samprada Singh, Founder and Chairman Emeritus July 27, 2019
Q4FY19 Results, Press Release and Investor Presentation May 30, 2019
Q4FY19 Conference Call Invite May 22, 2019
US FDA Inspection at Alkem 's formulation manufacturing facility at Baddi May 17, 2019
Update on USFDA inspection at St. Louis formulation facility May 15, 2019
Update on USFDA Inspection at St. Louis Facility March 22, 2019
Q3FY19 Financial Results February 08, 2019
Q3FY19 Press Release and Investor Presentation February 08, 2019
Update on USFDA Inspection at St. Louis Facility February 06, 2019
Q3FY19 Conference Call Invite February 01, 2019
Update on USFDA Inspection at Daman Facility January 18, 2019
Closure of US FDA Inspection at Alkem’s manufacturing facility located at St. Louis, USA December 04, 2018
Update on US FDA Inspection at Alkem’s Bioequivalence Facility at Taloja November 15, 2018
Q2FY19 Press Release and Investor Presentation November 02, 2018
Q2FY19 Financial Results November 02, 2018
Q2FY19 Conference Call Invite October 24, 2018
Mandatory Dematerialization for transfer of securities October 01, 2018
Update on the US FDA Inspection at Manufacturing Facility at California, USA August 11, 2018
Update on the US FDA Inspection at Baddi Formulation Facility August 10, 2018
Q1FY19 Financial Results August 10, 2018
Q1FY19 Press Release and Investor Presentation August 10, 2018
Q1FY19 Conference Call Invite August 01, 2018
Alkem receives EIR from the US FDA for its Daman formulation facility July 24, 2018
Q4FY18 Financial Results May 30, 2018
Q4FY18 Press Release and Investor Presentation May 30, 2018
Q4FY18 Conference Call Invite May 23, 2018
Update on USFDA inspection at Daman and St. Louis Facility, USA March 28, 2018
Q3FY18 Financial Results February 09, 2018
Q3FY18 Press Release and Investor Presentation February 09, 2018
Q3FY18 Conference Call Invite February 01, 2018
Alkem receives EIR from the US FDA for its Baddi formulation facility January 10, 2018
Q2FY18 Press Release and Investor Presentation November 10, 2017
Q2FY18 Financial Results November 10, 2017
Update on USFDA inspection at St. Louis Facility, USA October 30, 2017
Update on US FDA Inspection at Alkem's Baddi Facility September 18, 2017
Q1FY18 Financial Results August 11, 2017
Q1FY18 Press Release and Investor Presentation August 11, 2017
Q1FY18 Conference Call Invite July 28, 2017
Update on US FDA inspection for Bioequivalence Facility at Taloja July 14, 2017
Q4FY17 Financial Results May 26, 2017
Q4FY17 Press Release and Investor Presentation May 26, 2017
Alkem receives EIR from the US FDA for its Baddi Facility May 23, 2017
Q4FY17 Conference Call Invite May 18, 2017
Alkem receives EIR from the USFDA for Ankaleshwar facility March 29, 2017
Q3FY17 Financial Results February 10, 2017
Q3FY17 Press Release and Investor Presentation February 10, 2017
Alkem enters into an alliance with Haw Par for Tiger Balm products in India February 07, 2017
Q3FY17 Conference Call Invite January 25, 2017
Alkem receives EIR from the US FDA for its Daman formulation facility December 23, 2016
Update on USFDA inspection at Ankleshwar API facility December 12, 2016
Q2FY17 Financial Results November 11, 2016
Q2FY17 Press Release and Investor Presentation November 11, 2016
Q2FY17 Conference Call Invite November 07, 2016
Update on US FDA Bio-analytical Inspection at Daman Facility October 28, 2016
Update on US FDA inspection at Daman Facility September 29, 2016
Q1FY17 Financial Results August 12, 2016
Q1FY17 Press Release and Investor Presentation August 12, 2016
Successful US FDA Inspection at Alkem's Bioequivalence Facility at Taloja August 11, 2016
Q1FY17 Conference Call Invite August 02, 2016
EMA recommendations June 2016 June 25, 2016
Clarification on News Report June 09, 2016
Closure of UK MHRA inspection for Bioequivalence Facility at Taloja June 07, 2016
Q4FY16 Press Release May 27, 2016
Q4FY16 & FY16 Financial Results May 27, 2016
Favourable Competition Appellate Tribunal Order May 10, 2016
Q4 & FY16 Conference Call Invite May 10, 2016
Clarification April 16, 2016
UK MHRA Inspection - Update March 31, 2016
Declaration of Interim Dividend and Record Date March 09, 2016
Alkem's Mandva Plant successfully obtains the Establishment Inspection Report from the US FDA March 07, 2016
Financial Results, Limited Review Report for December 31, 2015 February 12, 2016
Authorised KMPs to determine materiality of events or information February 12, 2016
Press Release and Analyst presentation on Q3FY16 Results February 12, 2016
Q1FY24 Results, Press Release and Investor Presentation
August 10, 2023
Alkem Laboratories forays into Ophthalmology
July 6, 2023
Alkem Laboratories launches Cetuxa. World’s first biosimilar of Cetuximab for Head and Neck Cancer.
May 29, 2023
Q4FY23 Results, Press Release and Investor Presentation
May 19, 2023
Closure of US FDA Inspection at Ankleshwar
April 7, 2023
Closure of US FDA Inspection at Indore
February 23, 2023
Q3FY23 Results, Press Release and Investor Presentation
February 10, 2023
Q2FY23 Results, Press Release and Investor Presentation
November 11, 2022
Update on US FDA Inspection at St. Louis, USA
November 10, 2022
Update on US FDA Inspection at St. Louis, USA
September 15, 2022
Q1FY23 Results, Press Release and Investor Presentation
August 05, 2022
Q1FY23 Conference Call Invite.
July 26, 2022
Update on USFDA Inspection at Alkem’s manufacturing facility located at Indore.
July 7, 2022
Update on US FDA Inspection at St. Louis, USA
June 18, 2022
Update on MHRA Inspection at Alkem’s Bioequivalence Center at Taloja
May 13, 2022
Q4FY22 Results, Press Release and Investor Presentation
May 13, 2022
Q4FY22 Conference Call Invite.
May 2, 2022
Update on US FDA Inspection at Alkem’s Bioequivalence Center at Taloja
Apr 14, 2022
Update on ISP Chile Inspection at Alkem’s manufacturing facility located at Baddi, India.
Apr 13, 2022
Update on ISP Chile Inspection at Alkem's manufacturing facility located at Daman, India
Apr 1, 2022